Some peptide-based medicines, including GLP-1 weight-loss drugs such as Ozempic and Wegovy, have become household names in recent years
Molecules 27 , 1816 (2022)
ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
Indini A, Di Guardo L, and Cimminiello C, et al (2019) Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma J Cancer Res Clin Oncol 145 (2) 511221 52
